@keepupwithkoi's day 20 GLP-1 update, fact-checked

What did @keepupwithkoi actually say?

Koi is on day 20 of oral semaglutide (Wegovy pill, not the injectable), currently at 1.5 mg with a planned step-up to 4 mg. Her main claims: the pill "does suppress your appetite" and makes you "feel fuller longer," she didn't feel real effects until week three, she's using it to support intermittent fasting (eating window noon to 6 p.m.), and she takes fiber, a multivitamin, and a probiotic alongside it. She's avoiding the scale until the one-month mark. She also notes that fiber is "very important" to prevent constipation while on this medication. That's a reasonable, experience-based account. Nothing she says is reckless, and she's careful to note it's "not a miracle drug."

Does the science back this up?

Mostly, yes. Oral semaglutide (rybelsus/Wegovy pill) works by activating GLP-1 receptors in the gut and brain, reducing appetite and slowing gastric emptying. The OASIS 1 trial (Knop et al., 2023, NEJM) tested the 50 mg oral semaglutide formulation and showed significant weight loss versus placebo, confirming appetite suppression as the core mechanism. However, the doses Koi mentions, 1.5 mg and 4 mg, are the titration doses for the Wegovy oral formulation, which tops out at 50 mg for weight management. At those early titration levels, the pharmacodynamic effect is real but modest. Her observation that effects took until week three to feel meaningful is consistent with published pharmacokinetic data showing oral semaglutide requires steady-state accumulation. The fiber recommendation also has solid backing. GLP-1 medications slow GI motility, and constipation is a documented side effect, reported in roughly 11 percent of participants in clinical trials (Davies et al., 2021, Lancet).

What did they get wrong (or right)?

She got more right than wrong. The appetite suppression mechanism is accurate. The week-three onset observation lines up with clinical reality. The fiber advice is genuinely sound and underemphasized in most social media GLP-1 content.

One thing worth flagging: she says she's "on her cycle" and that weight readings "wouldn't be accurate anyway." Menstrual cycle-related water retention is real, typically one to five pounds depending on the individual (Brun et al., 2018, Journal of Clinical Medicine), so waiting for a more stable measurement window is actually reasonable, not an excuse to avoid the scale.

The intermittent fasting combination is where it gets more nuanced. Pairing GLP-1 therapy with a restricted eating window can amplify caloric reduction, but there's limited trial data specifically on oral semaglutide plus time-restricted eating. The risk of undereating protein and micronutrients increases when two appetite-suppressing strategies stack. She doesn't mention protein intake at all, and that's a real gap in her update.

What should you actually know?

If you're starting oral semaglutide, a few things Koi doesn't cover matter a lot. Oral semaglutide has notoriously variable absorption. It must be taken fasting, with no more than 4 oz of plain water, and you need to wait 30 minutes before eating or taking other medications or supplements. Taking fiber at the same time, which she correctly says she doesn't do, would significantly reduce absorption. Timing is not optional with this drug.

The 1.5 mg to 4 mg titration she describes is a legitimate step in the Wegovy oral protocol, designed to minimize nausea and GI side effects before reaching therapeutic doses. But early titration doses are not the therapeutic dose. Weight loss results at these early stages are not predictive of final outcomes. Social media timelines at day 20 capture the early tolerability phase, not the efficacy phase.

Also worth stating plainly: compounded semaglutide is not the same as FDA-approved Wegovy or Ozempic. If Koi is on an FDA-approved product, that's one context. If it's compounded, the formulation, absorption, and dosing can differ substantially, and that distinction matters for anyone trying to replicate her experience.